RS60982B1 - Jedinjenja korisna kao inhibitori kinaze - Google Patents
Jedinjenja korisna kao inhibitori kinazeInfo
- Publication number
- RS60982B1 RS60982B1 RS20201291A RSP20201291A RS60982B1 RS 60982 B1 RS60982 B1 RS 60982B1 RS 20201291 A RS20201291 A RS 20201291A RS P20201291 A RSP20201291 A RS P20201291A RS 60982 B1 RS60982 B1 RS 60982B1
- Authority
- RS
- Serbia
- Prior art keywords
- kinase inhibitors
- compounds useful
- compounds
- useful
- kinase
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522245.8A GB201522245D0 (en) | 2015-12-16 | 2015-12-16 | Compounds useful as kinase inhibitors |
| GBGB1613945.3A GB201613945D0 (en) | 2016-08-15 | 2016-08-15 | Compounds useful as kinase inhibitors |
| EP16816363.2A EP3390395B1 (en) | 2015-12-16 | 2016-12-16 | Compounds useful as kinase inhibitors |
| PCT/GB2016/053968 WO2017103611A1 (en) | 2015-12-16 | 2016-12-16 | Compounds useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60982B1 true RS60982B1 (sr) | 2020-11-30 |
Family
ID=57590725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20201291A RS60982B1 (sr) | 2015-12-16 | 2016-12-16 | Jedinjenja korisna kao inhibitori kinaze |
Country Status (36)
| Country | Link |
|---|---|
| US (7) | US10695323B2 (sr) |
| EP (2) | EP3782994A1 (sr) |
| JP (3) | JP6731483B2 (sr) |
| KR (2) | KR102215792B1 (sr) |
| CN (9) | CN114716381A (sr) |
| AU (4) | AU2016373530B2 (sr) |
| CA (1) | CA3008488C (sr) |
| CL (1) | CL2018001591A1 (sr) |
| CO (1) | CO2018006164A2 (sr) |
| CR (1) | CR20180367A (sr) |
| CY (1) | CY1123561T1 (sr) |
| DK (1) | DK3390395T3 (sr) |
| EA (1) | EA035132B1 (sr) |
| ES (1) | ES2828431T3 (sr) |
| FI (1) | FIC20240004I1 (sr) |
| FR (1) | FR24C1009I1 (sr) |
| HK (1) | HK1263254A1 (sr) |
| HR (1) | HRP20201835T1 (sr) |
| HU (2) | HUE051921T2 (sr) |
| IL (4) | IL285976B2 (sr) |
| LT (1) | LT3390395T (sr) |
| MA (2) | MA49809A1 (sr) |
| MD (1) | MD3390395T2 (sr) |
| MX (2) | MX2018007267A (sr) |
| NL (1) | NL301262I2 (sr) |
| NZ (1) | NZ743553A (sr) |
| PE (3) | PE20220507A1 (sr) |
| PH (1) | PH12018501268A1 (sr) |
| PT (1) | PT3390395T (sr) |
| RS (1) | RS60982B1 (sr) |
| SG (2) | SG11201805044WA (sr) |
| SI (1) | SI3390395T1 (sr) |
| TN (1) | TN2018000213A1 (sr) |
| UA (2) | UA127863C2 (sr) |
| WO (1) | WO2017103611A1 (sr) |
| ZA (4) | ZA201804137B (sr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410430D0 (en) | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| KR20180109842A (ko) | 2015-09-16 | 2018-10-08 | 록쏘 온콜로지, 인코포레이티드 | 화합물 |
| CN114716381A (zh) * | 2015-12-16 | 2022-07-08 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| GB201801226D0 (en) | 2018-01-25 | 2018-03-14 | Redx Pharma Plc | Modulators of Rho-associated protein kinase |
| EP3774782A2 (en) * | 2018-04-06 | 2021-02-17 | Black Belt TX Ltd | Atf6 inhibitors and uses thereof |
| JP6995195B2 (ja) | 2018-05-18 | 2022-02-04 | 富士フイルム株式会社 | ３－ジフルオロメチルピラゾール化合物の製造方法及び３－ジフルオロメチルピラゾール－４－カルボン酸化合物の製造方法、並びに、ピラゾリジン化合物 |
| CA3224945A1 (en) * | 2018-07-31 | 2020-02-06 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| EP4010333A1 (en) | 2019-08-09 | 2022-06-15 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| WO2021053234A1 (en) * | 2019-09-19 | 2021-03-25 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Compounds and compositions for treating kidney disease |
| CN110724135B (zh) * | 2019-11-18 | 2023-04-28 | 上海医药工业研究院有限公司 | 一种艾拉普林中间体及其制备方法 |
| BR112022009716A2 (pt) * | 2019-12-06 | 2022-08-09 | Loxo Oncology Inc | Dosagem de um inibidor de tirosina quinase de bruton |
| WO2021180107A1 (en) * | 2020-03-12 | 2021-09-16 | Fochon Pharmaceuticals, Ltd. | Compounds useful as kinase inhibitors |
| TWI809489B (zh) * | 2020-09-10 | 2023-07-21 | 美商絡速藥業公司 | 用於製備(s)-5-胺基-3-(4-((5-氟-2-甲氧基苯甲醯胺基)甲基)苯基)-1-(1,1,1-三氟丙烷-2-基)-1h-吡唑-4-甲醯胺之方法及中間體 |
| CN112386597B (zh) * | 2020-10-15 | 2022-03-15 | 天津济坤医药科技有限公司 | 泽布替尼在制备治疗肺纤维化疾病药物中的应用 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CN116348453A (zh) * | 2021-04-25 | 2023-06-27 | 烨辉医药科技(上海)有限公司 | 杂芳族甲酰胺化合物及其用途 |
| EP4337196A1 (en) | 2021-05-14 | 2024-03-20 | Loxo Oncology, Inc. | Cocrystalline forms of a bruton's tyrosine kinase inhibitor |
| IL309427A (en) * | 2021-07-01 | 2024-02-01 | Hangzhou Healzen Therapeutics Co Ltd | TYROSINE KINASE AND MUTANT DEGRADER, Broughton's composition and application |
| CN115611810A (zh) * | 2021-07-16 | 2023-01-17 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑类化合物及包含该化合物的组合物及其用途 |
| WO2023110970A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Macrocyclic btk inhibitors |
| WO2023143355A1 (en) * | 2022-01-28 | 2023-08-03 | Hansoh Bio Llc | Azacycle amide derivative, preparation methods and medicinal uses thereof |
| WO2023174397A1 (en) * | 2022-03-18 | 2023-09-21 | Insilico Medicine Ip Limited | Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof |
| CN115894376A (zh) * | 2022-12-15 | 2023-04-04 | 南京雷正医药科技有限公司 | 一种芳香族酰胺类化合物、药物组合物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212327B8 (en) | 1999-09-17 | 2004-02-25 | Abbott GmbH & Co. KG | Pyrazolopyrimidines as therapeutic agents |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US6291504B1 (en) * | 1999-10-20 | 2001-09-18 | Dupont Pharmaceuticals Company | Acylsemicarbazides and their uses |
| US20030225098A1 (en) | 2002-03-21 | 2003-12-04 | Hirst Gavin C. | Kinase inhibitors |
| EP2530083B1 (en) | 2006-09-22 | 2016-04-27 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| MX2009003650A (es) * | 2006-10-06 | 2009-04-22 | Abbott Lab | Nuevos imidazotiazoles e imidazoxazoles. |
| EP2089391B1 (en) | 2006-11-03 | 2013-01-16 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| NZ589843A (en) | 2008-06-27 | 2012-12-21 | Avila Therapeutics Inc | Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors |
| EP3311818A3 (en) | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| ES2386408T3 (es) * | 2008-07-24 | 2012-08-20 | Nerviano Medical Sciences S.R.L. | 3,4-Diarilpirazoles como inhibidores de proteína quinasa |
| US8426428B2 (en) | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| TWI582091B (zh) * | 2010-06-30 | 2017-05-11 | 艾諾屋製藥公司 | 可溶性鳥苷酸環化酶（ｓＧＣ）刺激物 |
| PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
| MX355728B (es) | 2011-05-17 | 2018-04-27 | Univ California | Inhibidores de cinasas. |
| WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2013191965A1 (en) | 2012-06-18 | 2013-12-27 | Principia Biopharma Inc. | Reversible covalent pyrrolo- or pyrazolopyrimidines useful for the treatment cancer and autoimmune diseases |
| WO2014022569A1 (en) | 2012-08-03 | 2014-02-06 | Principia Biopharma Inc. | Treatment of dry eye |
| GEP201706748B (en) * | 2012-08-10 | 2017-10-10 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| GB201214750D0 (en) * | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| MX2015005422A (es) * | 2012-11-02 | 2015-08-05 | Pfizer | Inhibidores de la tirosina-quinasa de bruton. |
| CN103848810A (zh) * | 2012-11-30 | 2014-06-11 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| GB201309085D0 (en) | 2013-05-20 | 2013-07-03 | Redx Pharma Ltd | Compounds |
| EP3052476B1 (en) * | 2013-09-30 | 2020-07-15 | Guangzhou InnoCare Pharma Tech Co., Ltd. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
| WO2015075051A1 (en) * | 2013-11-19 | 2015-05-28 | Universitaet Des Saarlandes | Allosteric inhibitors of atypical protein kinases c |
| US9637486B2 (en) | 2013-12-20 | 2017-05-02 | Merck Sharp & Dohme Corp. | Btk inhibitors |
| JP6504548B2 (ja) | 2014-02-21 | 2019-04-24 | プリンシピア バイオファーマ インコーポレイテッド | Ｂｔｋ阻害剤の塩および固体形態 |
| GB201404987D0 (en) * | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| CN105085474B (zh) * | 2014-05-07 | 2018-05-18 | 北京赛林泰医药技术有限公司 | 鲁顿酪氨酸激酶抑制剂 |
| GB201410430D0 (en) * | 2014-06-11 | 2014-07-23 | Redx Pharma Ltd | Compounds |
| AU2016212230B2 (en) | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| GB2548542A (en) * | 2015-06-16 | 2017-09-27 | Redx Pharma Plc | Compounds |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| KR20180109842A (ko) | 2015-09-16 | 2018-10-08 | 록쏘 온콜로지, 인코포레이티드 | 화합물 |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CN114716381A (zh) | 2015-12-16 | 2022-07-08 | 洛克索肿瘤学股份有限公司 | 可用作激酶抑制剂的化合物 |
| EP3389831A4 (en) | 2015-12-16 | 2019-07-31 | Ecolab USA Inc. | PEROXYAMENTIC ACID COMPOSITIONS FOR MEMBRANE FILTRATION CLEANING |
| DK3390390T3 (da) | 2015-12-16 | 2021-12-06 | Boehringer Ingelheim Int | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme |
| WO2017100856A1 (en) | 2015-12-16 | 2017-06-22 | Starpharma Pty Ltd | Dendrimer and formulations thereof |
| KR20180095577A (ko) | 2015-12-16 | 2018-08-27 | 브리스톨-마이어스 스큅 컴퍼니 | Apj 수용체의 효능제로서의 헤테로아릴히드록시피리미디논 |
-
2016
- 2016-12-16 CN CN202210310724.0A patent/CN114716381A/zh active Pending
- 2016-12-16 CN CN202111022492.0A patent/CN113636978A/zh active Pending
- 2016-12-16 CN CN201680073031.7A patent/CN108473481B/zh active Active
- 2016-12-16 PE PE2021001581A patent/PE20220507A1/es unknown
- 2016-12-16 CN CN202210311970.8A patent/CN114573510A/zh active Pending
- 2016-12-16 UA UAA202003795A patent/UA127863C2/uk unknown
- 2016-12-16 SG SG11201805044WA patent/SG11201805044WA/en unknown
- 2016-12-16 CN CN202210312076.2A patent/CN114621146A/zh active Pending
- 2016-12-16 MD MDE20181001T patent/MD3390395T2/ro unknown
- 2016-12-16 SI SI201630920T patent/SI3390395T1/sl unknown
- 2016-12-16 CA CA3008488A patent/CA3008488C/en active Active
- 2016-12-16 CN CN202111022488.4A patent/CN113603645A/zh active Pending
- 2016-12-16 MX MX2018007267A patent/MX2018007267A/es unknown
- 2016-12-16 PE PE2018001143A patent/PE20181449A1/es unknown
- 2016-12-16 WO PCT/GB2016/053968 patent/WO2017103611A1/en active Application Filing
- 2016-12-16 HU HUE16816363A patent/HUE051921T2/hu unknown
- 2016-12-16 DK DK16816363.2T patent/DK3390395T3/da active
- 2016-12-16 US US16/063,542 patent/US10695323B2/en active Active
- 2016-12-16 MA MA49809A patent/MA49809A1/fr unknown
- 2016-12-16 AU AU2016373530A patent/AU2016373530B2/en active Active
- 2016-12-16 EP EP20194724.9A patent/EP3782994A1/en active Pending
- 2016-12-16 IL IL285976A patent/IL285976B2/en unknown
- 2016-12-16 LT LTEP16816363.2T patent/LT3390395T/lt unknown
- 2016-12-16 MA MA055064A patent/MA55064A/fr unknown
- 2016-12-16 PE PE2021001592A patent/PE20220502A1/es unknown
- 2016-12-16 CN CN202210312050.8A patent/CN114591242A/zh active Pending
- 2016-12-16 PT PT168163632T patent/PT3390395T/pt unknown
- 2016-12-16 KR KR1020187020225A patent/KR102215792B1/ko active IP Right Grant
- 2016-12-16 CN CN202210312064.XA patent/CN114605327A/zh active Pending
- 2016-12-16 EP EP16816363.2A patent/EP3390395B1/en active Active
- 2016-12-16 CN CN202210311995.8A patent/CN114634447A/zh active Pending
- 2016-12-16 TN TNP/2018/000213A patent/TN2018000213A1/en unknown
- 2016-12-16 NZ NZ743553A patent/NZ743553A/en unknown
- 2016-12-16 KR KR1020217003683A patent/KR20210018530A/ko active Application Filing
- 2016-12-16 MX MX2021003478A patent/MX2021003478A/es unknown
- 2016-12-16 UA UAA201807294A patent/UA122258C2/uk unknown
- 2016-12-16 CR CR20180367A patent/CR20180367A/es unknown
- 2016-12-16 CO CONC2018/0006164A patent/CO2018006164A2/es unknown
- 2016-12-16 ES ES16816363T patent/ES2828431T3/es active Active
- 2016-12-16 RS RS20201291A patent/RS60982B1/sr unknown
- 2016-12-16 JP JP2018532035A patent/JP6731483B2/ja active Active
- 2016-12-16 SG SG10202012498TA patent/SG10202012498TA/en unknown
- 2016-12-16 EA EA201891268A patent/EA035132B1/ru not_active IP Right Cessation
-
2018
- 2018-06-10 IL IL259923A patent/IL259923B/en active IP Right Grant
- 2018-06-13 PH PH12018501268A patent/PH12018501268A1/en unknown
- 2018-06-14 CL CL2018001591A patent/CL2018001591A1/es unknown
- 2018-06-20 ZA ZA2018/04137A patent/ZA201804137B/en unknown
- 2018-08-22 US US16/109,162 patent/US10342780B2/en active Active
- 2018-08-27 US US16/113,661 patent/US10464905B2/en active Active
- 2018-11-06 HK HK18114157.0A patent/HK1263254A1/zh unknown
-
2020
- 2020-05-13 US US15/930,657 patent/US10918622B2/en active Active
- 2020-07-06 JP JP2020116636A patent/JP7086140B2/ja active Active
- 2020-07-26 IL IL276283A patent/IL276283B/en active IP Right Grant
- 2020-11-16 CY CY20201101090T patent/CY1123561T1/el unknown
- 2020-11-19 HR HRP20201835TT patent/HRP20201835T1/hr unknown
- 2020-12-15 US US17/122,103 patent/US11471441B2/en active Active
-
2021
- 2021-01-26 ZA ZA2021/00544A patent/ZA202100544B/en unknown
- 2021-02-24 IL IL281067A patent/IL281067B/en unknown
- 2021-03-23 AU AU2021201811A patent/AU2021201811B2/en active Active
- 2021-08-31 AU AU2021225162A patent/AU2021225162B2/en active Active
- 2021-08-31 AU AU2021225161A patent/AU2021225161B2/en active Active
- 2021-10-05 ZA ZA2021/07472A patent/ZA202107472B/en unknown
- 2021-10-05 ZA ZA2021/07471A patent/ZA202107471B/en unknown
- 2021-11-12 US US17/525,350 patent/US11826351B2/en active Active
-
2022
- 2022-06-07 JP JP2022092275A patent/JP7419437B2/ja active Active
-
2023
- 2023-07-31 US US18/362,249 patent/US20230372298A1/en active Pending
-
2024
- 2024-02-27 HU HUS2400003C patent/HUS2400003I1/hu unknown
- 2024-03-01 FI FIC20240004C patent/FIC20240004I1/fi unknown
- 2024-03-04 FR FR24C1009C patent/FR24C1009I1/fr active Active
- 2024-03-06 NL NL301262C patent/NL301262I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400003I1 (hu) | Kináz inhibitorként alkalmas vegyületek | |
| ZA201700115B (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
| HUE059324T2 (hu) | Heterociklusos vegyületek, mint PI3K-gamma inhibitorok | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL268614B (en) | Aminotriazolopyridines as kinase inhibitors | |
| IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
| IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL266150A (en) | Amide compounds as kinase inhibitors | |
| EP3102571A4 (en) | SUBSTITUTED PYRIMIDINES USEFUL AS EGFR-T790M KINASE INHIBITORS | |
| HK1253576A1 (zh) | 作為mnk抑制劑的吡咯並嘧啶化合物 | |
| GB201613945D0 (en) | Compounds useful as kinase inhibitors | |
| GB201522245D0 (en) | Compounds useful as kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201519381D0 (en) | Kinase inhibitors |